Management of opioid-induced constipation in cancer patients: Focus on methylnaltrexone

Clinical Drug Investigation

Volumn 32, Issue 5, 2012, Pages 293-301

  Gatti, Antonio ^a   Sabato, Alessandro Fabrizio ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; METHADONE; OPIATE;

ADVANCED CANCER; CANCER PAIN; CANCER PATIENT; CONSTIPATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; MAXIMUM PLASMA CONCENTRATION; OPIOID INDUCED CONSTIPATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANALGESICS, OPIOID; CONSTIPATION; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; NEOPLASMS; PAIN; PALLIATIVE CARE; QUATERNARY AMMONIUM COMPOUNDS;

EID: 84859803846     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11598000-000000000-00000     Document Type: Review

References (40)

1. Deibert P, Xander C, Blum HE, et al. Methylnaltrexone: The evidence for its use in the management of opioid-induced constipation. Core Evid 2010; 4: 247-258
2. Raphael J, Hester J, Ahmedzai S, et al. Cancer pain. Part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain. A perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med 2010; 11: 872-896
3. Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician 2010; 56: 514-7, e202-5
4. Abernethy AP, Wheeler JL, Zafar SY. Detailing of gastrointestinal symptoms in cancer patients with advanced disease: New methodologies, new insights, and a proposed approach. Curr Opin Support Palliat Care 2009; 3: 41-49
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Palliative care. V.1.2010 [online]. Available from URL: Http://www.nccn.org/professionals/physician-gls/pdf/palliative.pdf [Accessed 2011 Mar 2]
6. National Health Service Scotland. Palliative care guidelines: constipation [online]. Available from URL: Http://www. palliativecareguidelines. scot.nhs.uk/documents/Constipation final.pdf [Accessed 2011 Mar 2]
7. McCrea GL, Miaskowski C, Stotts NA, et al. Pathophysiology of constipation in the older adult.World JGastroenterol 2008; 14: 2631-8
8. Rao SS, Go JT. Update on the management of constipation in the elderly: New treatment options. Clin Interv Aging 2010; 5: 163-171
9. Camilleri M. Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil 2005; 17: 157-65 (Pubitemid 40476675)
10. Manara L, Bianchi G, Ferretti P, et al. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther 1986; 237: 945-949 (Pubitemid 16088118)
11. TaVani A, Bianchi G, Ferretti P, et al. Morphine is most effective on gastrointestinal propulsion in rats by intraperitoneal route: evidence for local action. Life Sci 1980; 27: 2211-7 (Pubitemid 11177362)
12. Dunlop GM. A study of the relative frequency and importance of gastrointestinal symptoms and weakness in patients with far advanced cancer: Student paper. Palliat. Med. 1990; 4: 37-43
13. Holmes S. Use of a modified symptom distress scale in assessment of the cancer patient. Int J Nurs Stud 1989; 26: 69-79
14. Choi YS, Billings JA. Opioid antagonists: A review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage 2002; 24: 71-90
15. Drossman DA. Introduction: The Rome Foundation and Rome III. Neurogastroenterol Motil 2007; 19: 783-786
16. Thomas J. Cancer-related constipation. Curr Oncol Rep 2007; 9: 278-84 (Pubitemid 47045162)
17. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358: 2332-43 (Pubitemid 351749157)
18. Shaiova L, Rim F, Friedman D, et al. A review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid-induced constipation. Palliat Support Care 2007; 5: 161-166
19. Yuan CS, Foss JF, O'ConnorM, et al. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: A pilot study. Pain 1999; 83: 631-635
20. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: A randomized controlled trial. JAMA 2000; 283: 367-72 (Pubitemid 30051755)
21. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: A double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996; 59: 469-75 (Pubitemid 26151630)
22. Yuan CS, Foss JF, Osinski J, et al. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 1997; 61: 467-75 (Pubitemid 27195949)
23. Yuan CS, Wei G, Foss JF, et al. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: A double-blind randomized placebocontrolled trial. J Pharmacol Exp Ther 2002; 300: 118-23 (Pubitemid 34028517)
24. Garnock-Jones KP, McKeage K. Methylnaltrexone. Drugs 2010; 70: 919-28
25. Bianchi G, Fiocchi R, TaVani A, et al. Quaternary narcotic antagonists'relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-Treated rats as an index of peripheral selectivity. Life Sci 1982; 30: 1875-83 (Pubitemid 12098880)
26. Gmerek DE, Cowan A, Woods JH. Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J Pharmacol Exp Ther 1986; 236: 8-13 (Pubitemid 16186117)
27. Walker MJ, Le AD, Poulos CX, et al. Role of central versus peripheral opioid receptors in analgesia induced by repeated administration of opioid antagonists. Psychopharmacology (Berl) 1991; 104: 164-166
28. Singleton PA, Mambetsariev N, Lennon FE, et al. Methylnaltrexone potentiates the anti-Angiogenic effects of mTOR inhibitors. J Angiogenes Res 2010; 2: 5
29. Wang CZ, Li XL, Sun S, et al. Methylnaltrexone, a peripherally acting opioid receptor antagonist, enhances tumoricidal effects of 5-Fu on human carcinoma cells. Anticancer Res 2009; 29: 2927-32
30. Yuan CS, Sun S, Attele A, et al. Methylnaltrexone potentiates body weight and fat reduction with leptin. J Opioid Manag 2009; 5: 373-378
31. Yuan CS, Wang CZ, Attele A, et al. Methylnaltrexone reduced body weight gain in ob/ob mice. J Opioid Manag 2009; 5: 213-218
32. Rosow CE, Gomery P, Chen TY, et al. Reversal of opioidinduced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin Pharmacol Ther 2007; 82: 48-53
33. Woo M, O'Connor M, Yuan CS, et al. Reversal of opioidinduced gastric dysfunction in a critically ill burn patient after methylnaltrexone. Anesth Analg 2008; 107: 1965-7
34. European Medicines Agency. Relistor-(methylnaltrexone bromide solution) EU prescribing information [online]. Available from URL: Http://www.ema.europa. eu/ema/in dex.jsp?curl=pages/medicines/human/medicines/000870/ human-med-001022.jsp&murl=menus/medicines/medici nes.jsp&mid= WC0b01ac058001d125 [Accessed 2011 Jan 30]
35. Pfizer. Relistor. Highlights of prescribing information [online]. Available from URL: Http://www.pfizerpro.com/ content/showlabeling.asp?id=499. [Accessed 2011 Jan 30]
36. Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioidinduced constipation in patients with advanced illness: A double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008; 35: 458-68 (Pubitemid 351601995)
37. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 2009; 7: 39-46
38. Earnshaw SR, Klok RM, Iyer S, et al. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness: A cost-effectiveness analysis. Aliment Pharmacol Ther 2010; 31: 911-21
39. Reichle FM, Conzen PF. Methylnaltrexone, a new peripheral mu-receptor antagonist for the prevention and treatment of opioid-induced extracerebral side effects. Curr Opin Investig Drugs 2008; 9: 90-100
40. Yuan CS, Israel RJ. Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opin Investig Drugs 2006; 15: 541-52